ELPEN invests €80M in Athens LifeTech Park, first biotech hub in SE Europe

Greek pharmaceutical company ELPEN announces €80 million investment to establish the Athens LifeTech Park, the first integrated biotechnology park in Southeast Europe. The project aims to bridge scientific research with commercial development and attract international investment, signaling a strategic push to position Greece as a regional biotech hub. Details on timeline and specific capabilities remain limited.